Jingxin C. Li

National Health Commission Key Laboratory Of Enteric Pathogenic Microbiology
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 126 publications

Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.

Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains.

Journal: Emerging microbes & infections

Published: June 22, 2026

Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China.

Post-marketing safety surveillance of Haemophilus influenzae Type b conjugate vaccine in children aged 3 months to 5 years in Jiangsu, China.

Journal: Human vaccines & immunotherapeutics

Published: May 30, 2026

A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China.

A self-controlled case series study on the safety of a live attenuated herpes zoster vaccine in China.

Journal: Expert review of vaccines

Published: February 04, 2026

Fc-mediated immune effector functions elicited by recombinant and live-attenuated herpes zoster vaccines.

Fc-mediated immune effector functions elicited by recombinant and live-attenuated herpes zoster vaccines.

Journal: Expert review of vaccines

Published: February 04, 2026

Development of a unified mass cytometry assay integrating activation-induced markers (AIMs) and cytokine profiling for high-throughput assessment of antigen-specific T cell responses.

Development of a unified mass cytometry assay integrating activation-induced markers (AIMs) and cytokine profiling for high-throughput assessment of antigen-specific T cell responses.

Journal: Human vaccines & immunotherapeutics

Published: January 30, 2026

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.

Modeling of antibody waning after heterologous boosting with Ad5-nCoV in individuals primed with two-dose CoronaVac previously.

Journal: Human vaccines & immunotherapeutics

Published: January 22, 2026

A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants.

A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants.

Journal: Infectious Disease Modelling

Published: November 09, 2025

Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance-from immune microenvironment crosstalk to therapeutic translation.

Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance-from immune microenvironment crosstalk to therapeutic translation.

Journal: Frontiers in immunology

Published: October 16, 2025

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20-45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial.

Immunogenicity and safety of an Escherichia coli-produced 9-valent human papillomavirus vaccine (types 6/11/16/18/31/33/45/52/58) in healthy Chinese women aged 20-45 years: a single-center, randomized, observer-blinded, positive controlled phase 2 clinical trial.

Journal: Frontiers in immunology

Published: September 16, 2025

Deep Mutational Scanning in Immunology: Techniques and Applications.

Deep Mutational Scanning in Immunology: Techniques and Applications.

Journal: Pathogens (Basel, Switzerland)

Published: September 11, 2025

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants.

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants.

Journal: Expert review of vaccines

Published: August 25, 2025

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.

Journal: Vaccine

Published: August 25, 2025

Showing 1-12 of 126

Last Updated: 09/26/2026